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Cerebrovascular homeostasis is maintained by the blood-brain barrier (BBB), which
forms a mechanical and functional barrier between systemic circulation and the
central nervous system (CNS). In patients with ischemic stroke, the recombinant
tissue-type plasminogen activator (rt-PA) is used to accelerate recanalization of
the occluded vessels. However, rt-PA is associated with a risk of increasing
intracranial bleeding (ICB). This effect is thought to be caused by the increase in
cerebrovascular permeability though various factors such as ischemic reperfusion
injury and the activation of matrix metalloproteinases (MMPs), but the detailed
mechanisms are unknown. It was recently found that rt-PA treatment enhances
BBB permeability not by disrupting the BBB, but by activating the vascular
endothelial growth factor (VEGF) system. The VEGF regulates both the dissociation of
endothelial cell (EC) junctions and endothelial endocytosis, and causes a subsequent
increase in vessel permeability through the VEGF receptor-2 (VEGFR-2) activation
in ECs. Here, we review the possibility that rt-PA increases the penetration
of toxic molecules derived from the bloodstream including rt-PA itself, without
disrupting the BBB, and contributes to these detrimental processes in the cerebral
parenchyma.
Keywords: brain ischemia, blood-brain barrier permeability, endothelial endocytosis, intracranial bleeding, tissue-
type plasminogen activator, vascular endothelial growth factor
INTRODUCTION
The recombinant tissue-type plasminogen activator (rt-PA), a serine proteinase, is a thrombolytic
agent that degrades fibrin clots through the activation of plasminogen to plasmin (Lijnen
and Collen, 1987). Although rt-PA given within 3 h from the onset of ischemic stroke
improves patients’ clinical outcome, it induces a 10-fold increase of symptomatic intracranial
Abbreviations: BBB, blood-brain barrier; BSA, bovine serum albumin; CNS, central nervous system; EC,
endothelial cell; ECM, extracellular matrix; FITC, fluorescein isothiocyanate; HIF, hypoxia-inducible factor; ICB,
intracranial bleeding; LRP, low-density lipoprotein receptor-related protein; MCA, middle cerebral artery; MMP,
metalloproteinase; ROS, reactive radical oxide species; rt-PA, recombinant tissue-type plasminogen activator; VEGF,
vascular endothelial growth factor; TJ, tight junction; ZO, zonula occludens.
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hemorrhage (The National Institute of Neurological Disorders
and Stroke rt-PA Stroke Study Group, 1995). Furthermore, rt-PA
treatment delayed beyond 3 h is associated with an increased
risk of hemorrhagic transformation with enhanced brain injury
(Clark et al., 1999). Subsequently, the European Cooperative
Acute Stroke Study showed that rt-PA administered between 3
and 4.5 h after the onset of symptoms significantly improved
the clinical outcomes of patients with acute ischemic stroke, but
it increased the risk of symptomatic intracranial hemorrhage.
It was confirmed that delayed treatment beyond 4.5 h was not
associated with a statistically significant benefit (Hacke et al.,
2008). A number of clinical studies using magnetic resonance
imaging provided evidence that rt-PA treatment is associated
with blood-brain barrier (BBB) breakdown (Kastrup et al., 2008;
Kassner et al., 2009), which also correlates with an increased risk
of hemorrhagic transformation during thrombolysis in ischemic
stroke (Kassner et al., 2009). These findings strongly suggest a
causal relationship between rt-PA and BBB breakdown in the
ischemic human brain.
Although the deleterious effect of rt-PA after ischemic stroke
has been widely accepted, it remains unclear whether many
blood-derived rt-PAs penetrate the brain and contribute to these
detrimental processes in the cerebral parenchyma. Intravenously
administered rt-PA has been shown to cross brain endothelial
cells (ECs) via two ways: (1) by binding to the surface;
and (2) transcytosis without compromising the BBB integrity
(Benchenane et al., 2005; López-Atalaya et al., 2007). rt-PA
was also found to enter the parenchyma under pathological
conditions where it further affects BBB breakdown (Su et al.,
2008). Some hypotheses have been proposed to explain how
rt-PA within the parenchyma exacerbates intracranial bleeding
(ICB) after ischemic stroke. Extracellular rt-PA canmediate some
of its actions either through plasmin; the degradation of laminin,
one of the extracellular matrix (ECM) proteins (Chen and
Strickland, 1997); the activation of microglia (Rogove and Tsirka,
1998); or the excessive induction of vascular remodeling and
angiogenesis via overactivation of metalloproteinases (MMPs;
Suzuki et al., 2007; Yamashita et al., 2009; Won et al., 2014) and
the vascular endothelial growth factor (VEGF; Kanazawa et al.,
2011; Suzuki et al., 2015). There is also evidence that rt-PA may
have a direct toxic effect on the ischemic brain (Wang et al., 1998;
Nagai et al., 1999), possibly through activation of the N-methyl-
D-aspartate receptor (NMDAR; Nicole et al., 2001). This may
be of particular importance given that rt-PA diffused within
the cerebral parenchyma after ischemia can have detrimental
effects including enhancing the neurotoxic processes (Kaur et al.,
2004).
In the present review, we firstly described BBB breakdown
by rt-PA, and then discussed the role of the enhancement
of BBB permeability without compromising BBB integrity on
BBB breakdown. Especially, we focus on the involvement
of VEGF in ECs as the first step in BBB breakdown by
the deleterious effect of rt-PA after ischemic stroke. In
addition, it is described the possibility that an inhibition the
enhancement of BBB permeability without compromising BBB
integrity may extend the therapeutic time widow by rt-PA for
ischemic stroke.
BBB AND ENDOTHELIAL TIGHT
JUNCTIONS
The BBB is formed by endothelial tight junctions (TJs) together
with pericytes, perivascular astrocytes, and basement membrane
in the vasculature. Furthermore, as cerebrovascular function is
regulated by the neuronal environment, the BBB and neurons
form a functional unit called the neurovascular unit. TJs
are constituted by multiple protein components that involve
transmembrane proteins (e.g., occludin, claudins, and junction-
associated molecules) linked to the actin cytoskeleton via
cytoplasmic zonula occludens (ZO) proteins. Transmembrane
proteins, occludin and claudins are critical for paracellular
function at the BBB (Hawkins and Davis, 2005). Claudins
are small transmembrane proteins (20–24 kDa) that span the
membrane four times; claudin-1, -3, and -5 are expressed in
ECs of the BBB. Occludin is a 60–65 kDa phosphoprotein highly
expressed in cerebral endothelia, but it is sparsely distributed in
peripheral endothelia (Hirase et al., 1997). The overexpression
of claudins can induce the formation of TJs, but the expression
of occludin does not lead to the formation of TJs. Thus, it is
likely that claudins form the primary seal of TJs, and occludin
acts as an additional support structure. Claudin and occludin are
anchored to the actin cytoskeleton via ZO-1 (Hawkins and Davis,
2005).
rt-PA and Reperfusion Injury
In patients with ischemic stroke, rt-PA increases the risk of
ICB via BBB breakdown through a number of mechanisms.
One of these mechanisms is thought to be by reperfusion
after the degradation of occlusive blood clots by rt-PA. Brain
parenchymal damage occurs because of a complex series of
events in the setting of ischemia followed by reperfusion
injury. These events start due to an interruption in blood
flow to the affected tissue followed by the depletion of
cellular energy resources and glycolysis at an anerobic substrate
level, with subsequent lactic acidosis, failure of the sodium
potassium pump, the release of glutamate, cytotoxic edema, and
free radical formation (Nour et al., 2013). The activation of
both innate and adaptive immune responses also creates free
radicals. This excessive generation of free radicals overwhelms
the system, which then becomes inefficient in scavenging
these molecules, leading to BBB breakdown. Furthermore,
ICB associated with ischemic infarction is recognized due to
ischemia followed by reperfusion, and both the rate of ICB
and stroke outcome can be increased by the duration of
reperfusion from the onset of vessel occlusion due to ischemic
stroke (Jickling et al., 2014). Additional injury is extensively
shown in the brain and in other tissues, which is mediated by
reactive radical oxide species (ROS). ROS contribute to BBB
disruption by several mechanisms: oxidative damage to cellular
molecules (i.e., proteins, lipids, and DNA); the activation of
MMPs and subsequent degradation of basement membrane;
cytoskeletal reorganization of ECs; the modulation of TJ proteins
and upregulation of inflammatory mediators; and subsequent
additional and extensive reperfusion injury (Kahles and Brandes,
2012).
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rt-PA Promotes ICB Through Mechanisms
Beyond its Role in Thrombolysis and
Reperfusion
rt-PA increases BBB permeability via degradations of basement
membrane and TJ proteins. These degradations are associated
with plasmin activation, low density lipoprotein receptor
associated protein-1 (LRP-1) stimulation, and MMPs induction
(Yamashita et al., 2009; Won et al., 2014). As a result, rt-PA
exacerbates ischemic brain damage and ICB by increasing BBB
permeability.
Plasmin, which is activated by rt-PA, can directly degrade
fibrin clots and basement membrane components such as
collagen IV (Mackay et al., 1990; Lukic-Panin et al., 2010),
laminin (Chen and Strickland, 1997) and fibronectin (Marchina
and Barlati, 1996), or via the activation of MMPs (Lijnen,
2001), which possess similar basement membrane dismantling
capabilities and damages the TJs (Jin et al., 2010).
LRP is one of the major binding sites of rt-PA (Bu
et al., 1992) on the cell surface. LRP, a member of the
lipoprotein receptor family, is a scavenger receptor that binds
a variety of biological ligands associated with the ECM and
is thought to be primarily involved in lipoprotein metabolism
(Herz et al., 1988), and in the clearance of protease-inhibitor
complexes in the adult brain (Bu et al., 1992). Furthermore,
the increase in BBB permeability by rt-PA occurs via the
activation of LRP (Yepes et al., 2003; Benchenane et al., 2005;
Su et al., 2008; Suzuki et al., 2009; Niego and Medcalf, 2014).
LRP is selectively upregulated in ECs under ischemic stress,
and LRP activation by binding to rt-PA stimulates signal
pathways such as the nuclear factor κB pathway (Suzuki et al.,
2009).
MMPs, a family of zinc endopeptidases, contribute to
tissue remodeling through the degradation of ECM proteins.
Although clarifying the precise timing and release of cells to
MMP after ischemia requires further study, MMPs, including
MMP-9 (gelatinase B), MMP-2 (gelatinase A), and MMP-3
(stromelysin-1), are thought to be key molecules involved
in BBB opening and ICB after ischemic stroke (Rosenberg
et al., 1995; Castellanos et al., 2003; Wang et al., 2003;
Suzuki et al., 2007; Mishiro et al., 2012; Jickling et al., 2014)
together with other brain proteases (i.e., plasmin, endogenous
t-PA, and urokinase; Wang and Shuaib, 2007). Claudin-5
and occludin, components of the TJs, contain extracellular
MMP cleavage sites and are a direct substrate of MMPs
(Wachtel et al., 1999; Yang et al., 2007), suggesting that
MMPs can degrade TJs directly. As the structural disruption
of the interaction between occludins and actin filaments can
lead to the perturbation of paracellular permeability (Madara
et al., 1986), the degradation of occludin by MMPs is likely
to trigger BBB opening. MMPs also degrade components
of basement membrane and contribute to BBB impairment,
vasogenic edema and hemorrhagic transformation (Rosell
et al., 2008). MMP-9 especially is believed to play a major
role in BBB disruption during ischemic stroke because
ischemic stress induces MMP-9 and the plasma MMP-9
concentration, which strongly correlate with patients’ stroke
severity (Horstmann et al., 2003; Jin et al., 2010; Reuter et al.,
2013).
MMP-3 is also thought to be involved in ICB due to delayed
rt-PA treatment. MMP-3 is produced by pericytes (Yang et al.,
2013) and ECs (Suzuki et al., 2007) after ischemic stroke.
The increase in ICB caused by the delayed rt-PA treatment
was impaired in mice with a gene deficiency of MMP-3, and
a broad spectrum MMP-inhibitor suppressed ICB in wild-
type mice but not in MMP-3 deficient mice (Suzuki et al.,
2007). MMP-3 can be activated by plasmin (Lijnen, 2001),
and it has a broad-spectrum substrate specificity, including
pro-MMP-9, which is activated by limited cleavage (Nagase
and Woessner, 1999). Furthermore, rt-PA treatment induced
MMP-3 selectively in ECs at the ischemic damaged area in
a mouse stroke model (Suzuki et al., 2007), and MMP-3 was
increased in a postmortem human stroke brain (Jickling et al.,
2014). These findings indicate that MMP-3 is also involved
in degrading the barrier of blood vessels and contributing
to ICB.
Increase in BBB Permeability by
Paracellular Transport and Transcytosis
rt-PA treatment is thought to enhance ICB via the acceleration
of BBB disruption after ischemic stroke. However, there is still
a possibility that rt-PA treatment enhances BBB permeability
without BBB disruption after ischemic stroke.
The BBB is composed of blood vessels whose ECs display
extremely low rates of transcellular vesicular transport
(transcytosis) due to pinocytic activity (Reese and Karnovsky,
1967; Pun et al., 2009; Saunders et al., 2012; Siegenthaler
et al., 2013). In concert with pericytes and astrocytes, this
unique brain endothelial barrier seals the central nervous
system (CNS) and controls substance influx and efflux
(Armulik et al., 2010; Bell et al., 2010; Daneman et al.,
2010). BBB permeability is regulated in response to various
stimulators or stressors, which can exert beneficial or
deleterious effects on the brain depending on the context,
timing, and functional cellular outcomes of signaling (Roux
and Couraud, 2005). BBB permeability can be increased via
two processes. The first is paracellular transport, which is
associated with loosening the TJs between ECs. The expression
of occludin, a component of TJs, is highly suppressed by
a number of pathological stresses, including oxidative
stress, and a decrease in the occludin expression results
in the increase in BBB permeability (Ramirez et al., 2009;
Lochhead et al., 2010). To enhance paracellular transport,
rt-PA seems to decrease occludin through ROS generation
associated with reperfusion and/or through the activation
of MMPs.
The second process is transcytosis, which is consistent with
endocytosis and involves vesicle transport to the opposite side
of the cell and exocytosis. Peripheral ECs display active vesicle
trafficking to deliver nutrients to peripheral tissues, whereas CNS
ECs express transporters to selectively traffic nutrients across the
BBB (Saunders et al., 2012; Siegenthaler et al., 2013). However, it
is still unclear when and how ECs are transported by transcytosis.
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VEGF
VEGF stimulates endocytosis and transcytosis (Horowitz and
Seerapu, 2012; Nakayama and Berger, 2013). VEGF binds to
two receptor-coupled protein tyrosine kinases (Tyr), VEGF
receptor 1 (VEGFR-1, Flt-1) and VEGFR-2 (i.e., fetal liver
kinase 1 [Flk-1] or the kinase insert domain receptor). VEGF
regulates the dissociation of TJs under ischemic condition
(Fischer et al., 2002; Figure 1) and endocytosis (Horowitz
and Seerapu, 2012), and the subsequent increase in vessel
permeability through VEGFR-2 activation, which contributes
to cerebral swelling at the early stage after ischemic stroke
(Abumiya et al., 2005). VEGF also has a fundamental role
in vascular remodeling and angiogenesis by increasing EC
proliferation, migration, and microvascular hyperpermeability
(Brown et al., 1992). The downstream elements of VEGFR-2
signaling include the Ras/Raf/MEK pathway, which leads to EC
proliferation; PI3K-AKT/PKB pathway, which supports EC
survival; and p38/MAPK-HSP27 pathway, which promotes
EC migration (Obermeier et al., 2013). Vascular remodeling is
an important component of recovery after stroke, although it
makes vessels to be leakier and prone to intracranial hemorrhage
(Durukan et al., 2009). Thus, they may also promote intracranial
hemorrhage.
VEGF is expressed in the normal adult brain, mainly in
epithelial cells of the choroid plexus, as well as in astrocytes
and neurons, such as granule cells of the cerebellum (Monacci
et al., 1993; Marti and Risau, 1998). VEGF expression is regulated
by extensive signaling pathways. Among them, hypoxia is a
strong inducer of VEGF messenger (m)-RNA expression in
many cells in vitro and in vivo (Banai et al., 1994; Ikeda
et al., 1995; Kovács et al., 1996; Hayashi et al., 1997). The two
transcription factors, hypoxia-inducible factor-1 (HIF-1) and
FIGURE 1 | Paracellular transport in the blood-brain barrier (BBB) by
the vascular endothelial growth factor (VEGF) under ischemic
condition. The binding of VEGF to the VEGF receptor-2 (VEGFR-2) induces
the activation of tyrosine kinase (Tyr), which leads to a decrease in the
expression of zonula occludens (ZO)-1. The changes in ZO-1 correlate with
small changes in action distribution, which induce disassembly of the tight
junction (TJ).
HIF-2 are involved in the regulation of VEGF expression. HIF-1
is composed of a hypoxia-regulated α-subunit and a β-subunit,
and is a basic helix-loop-helix heterodimeric transcription factor
activated by reduced oxygen tension (Wenger and Gassmann,
1997). HIF-1α is continuously produced and rapidly degraded
under normoxia (Sharp and Bernaudin, 2004), whereas it is
degraded slowly under hypoxia, and allowed rapid accumulation
and binding to hypoxia-responsive elements (Shi, 2009). HIF-2,
a homolog of HIF-1, is also involved in the regulation
of VEGF gene expression (Ema et al., 1997). HIF-2 has
an additional role in the regulation of VEGFR-2 (Kappel
et al., 1999). Although VEGF is induced in ECs through
HIF-1α (Tang et al., 2004), and the expression of HIF-1
and HIF-2 are increased in the border area of ischemic
stroke (Marti et al., 2000), the mechanisms by which VEGF
gene expression is regulated during cerebral ischemia remain
unclear.
One mechanism for the increase in VEGF secretion by cells
exposed to ischemia is an increase in its transcription rate
mediated by the binding of HIF-1 to a hypoxia-responsive
element in the 5′-flanking region of the VEGF gene, as is
observed in PC12 cells (Levy et al., 1995), bovine pulmonary
artery ECs (Liu et al., 1995), and Hep3B cells (Forsythe et al.,
1996). Other mechanisms include the increase in VEGF mRNA
stability (Ikeda et al., 1995) and efficient translation of VEGF
mRNA through an internal ribosome entry site (Stein et al.,
1998).
rt-PA, HIF-1, and VEGF
rt-PA increases VEGF expression in bone marrow-derived
myeloid cells, cultured cerebral cortical neurons, and ECs (Ohki
et al., 2010; Wu et al., 2012; Duan and Ni, 2014; Suzuki
et al., 2015). In addition, rt-PA affects HIF-1α regulation.
rt-PA induces HIF-1α accumulation in the ischemic brain and
accelerates HIF-1α accumulation mediated by the mammalian
target of rapamycin in cultured neurons (Wu et al., 2012).
rt-PA treatment after ischemia does not enhance the expression
of VEGF through the nuclear accumulation of HIF-1α in
a transformed mouse brain EC line, bEnd.3 (Suzuki et al.,
2015); instead, the overexpression of t-PA stimulates VEGF
expression in ECV304, a human immortalized EC due to the
stimulation of ERK/p38 signaling pathways (Duan and Ni,
2014). These findings suggest a possibility that rt-PA accelerates
the expression of VEGF via HIF-1α or the signal pathway
for the upregulation of HIF-1α in parallel without VEGF
induction.
The inhibition of VEGF signaling reduces rt-PA-related
ICB (Kanazawa et al., 2011; Suzuki et al., 2015), suggesting
that VEGF has a deleterious role in ICB. Similarly, VEGF
administered within 1–24 h from stroke onset increases in
the rate of BBB breakdown and hemorrhagic transformation,
and the size of infarction in rodents (Zhang et al., 2000;
Abumiya et al., 2005). Taken together that VEGF increases
microvascular permeability to blood plasma proteins within
minutes after its administration (Dvorak et al., 1995), the
induction of VEGF after ischemic stroke may enhance the
detrimental effects. In contrast, VEGF administered 48 h from
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stroke onset enhances angiogenesis and improves neurologic
recovery, and improves cerebral blood flow 28 days after stroke
(Zhang et al., 2000). The effect of VEGF on angiogenesis is
longer than on permeability. Newly formed vessels in ischemic
mouse brains are first visible within 4 days (Dellian et al.,
1996) and there is an increase in newly formed vessels in
ischemic mouse brains 10 days after VEGF treatment but
not in contralateral non-ischemic brains (Zechariah et al.,
2013). Thus, VEGF seems to have biphasic roles in stroke, it
promotes BBB breakdown and hemorrhagic transformation in
the early stage, within 24 h, but promotes BBB integrity and
vascular function in the late stage, over 48 h, after ischemic
stroke.
Paracellular Permeability by rt-PA
Increased paracellular permeability is correlated with the
disruption of TJs (Kevil et al., 2000; Mark and Davis, 2002;
Lee et al., 2004). Until now, however, the role of TJs in
vascular permeability of either plasma components or circulating
cells was supported by the results of only a few studies
(Martìn-Padura et al., 1998; Pedram et al., 2002). During
ischemic stroke, temporal hypoxemia for 10 min increased
BBB permeability associated with alterations in TJ protein
expression (Witt et al., 2003). Accordingly, immunoreactivity
of ZO-2 or claudin-5 was significantly reduced in infarct
regions compared with non-infarct regions 24 h after ischemia
(Fischer et al., 2007). However, according to ultrastructural
analyses at 5 and 25 h after ischemia, fluorescein isothiocyanate
(FITC)-albumin was extravased around vessels with intact TJs,
whereas the endothelium exhibited an enhanced transcellular
vesicle trafficking (Krueger et al., 2013). Additionally, the
morphology of TJ components identified by antibodies against
occludin and claudin-5 appears to be regularly maintained
in regions where FITC-albumin massively leaked into the
neuropil 25 h after ischemia (Krueger et al., 2013). A conclusive
time frame for TJ reassembly following the disruption of
ischemia is currently lacking. In Madin-Darby canine kidney
cells, permeability is returned to the same levels of the initial
condition 5 h after ATP repletion. After ATP depletion for
1 h and repletion for 3 h, occludin was once again found
almost exclusively at the level of the TJs. This reversible
shift is inhibited by the chelation of intracellular calcium.
In contrast, ZO-1 is not significantly altered during ATP
depletion or repletion (Ye et al., 1999). However, VEGF
specifically down-regulates claudin-5, occludin protein, and
mRNA. In the mouse cerebral cortex, the microinjection of
VEGF disrupted claudin-5 and occludin, and induced loss
of barrier function (Argaw et al., 2009). The continuity of
the ZO-1 expression was significantly disrupted during 1.5 h
of hypoxia in primary cultures isolated from porcine brain
ECs. Furthermore, VEGF alone or α-lipoic acid alone did
not change ZO-1 localization in the primary culture, however,
VEGF in combination with α-lipoic acid decreased the ZO-1
expression to nearly the same extent as 3 h of hypoxia (Fischer
et al., 2002). These results suggest that ischemia increases
the paracellular flux via the release of VEGF, which in turn
leads to the dislocalization, decreased expression, and enhanced
phosphorylation of TJs. As TJ proteins are responsible for the
paracellular permeability across the BBB, VEGF induced by
ischemia may increase paracellular permeability of BBB via
suppression of the expression of TJ proteins in the early stage
of ischemic stroke (Fischer et al., 2002; Argaw et al., 2009,
2012). However, it is possible that BBB permeability is increased
by TJs loosening in the early stage of ischemic stroke because
a study found intact TJs at 24 h after stroke (Krueger et al.,
2013).
Delayed rt-PA treatment enhances the fragmentation of
occludin and claudin-5 24 h after middle cerebral artery (MCA)
occlusion in rats (Won et al., 2014), and reduces claudin-5
at 24 h (Ishiguro et al., 2010) or occludin and ZO-1 at 48 h
after ischemia in mice (Mishiro et al., 2012). Furthermore, it
was found that blood levels of TJ proteins were higher in
patients with hemorrhagic transformation than in those without
hemorrhagic transformation (Kazmierski et al., 2012). These
findings indicate that delayed rt-PA treatment results in the
enhancement of ICB due to stroke by the loss of TJ proteins at
a relatively later stage, over 24 h, on ischemic stroke. However,
the role of TJ proteins in early ICB is still unclear. Delayed
rt-PA treatment may enhance the BBB permeability through
the paracellular pathway by the degradation of TJ proteins
without BBB breakdown as well as ischemia without rt-PA
treatment.
rt-PA Treatment and Endocytosis
The intravenous treatment of rt-PA does not increase either
albumin extravasation or ICB in naive mice (Cheng et al.,
2006; Su et al., 2008; Suzuki et al., 2015). Additionally, the
intraventricular injection of rt-PA does not increase Evans blue
extravasation in sham-operated mice (Yepes et al., 2003). In
contrast, an intravenous injection of rt-PA slightly increases the
Evans blue extravasation in native mice (Turner and Vink, 2012).
Furthermore, an intravenous injection of biotinylated rt-PA
with fluorescent dextran (77 kDa) is detected the extravasation
of rt-PA in the brain parenchyma of nonlesioned animals
(Benchenane et al., 2005), suggesting that rt-PA itself and other
plasma molecules can cross the intact BBB via transcytosis.
Similarly, we observed that delayed rt-PA treatment dramatically
increased endocytosis of cerebral ECs at the ischemic border
region together with an increase in the existence of gold-labeled
bovine serum albumin (BSA) administered intravenously at
the vascular lumen, inside ECs, in the basement layer of the
ECM and extravascular space without obvious TJ defects in
mice (Suzuki et al., 2015). This indicates that delayed rt-PA
treatment increased extravasation of BSA at the ischemic border
region in the early period after MCA occlusion by the additional
acceleration of transcytosis rather than by the degradation of
vascular structures. It is likely that the administration of rt-PA
accelerates extravasation of phagocytic vesicles, including rt-PA,
and interacting plasma plasminogen in the parenchyma by the
upregulation of transcytosis increases the likelihood of a plasmin-
dependent BBB alteration at the perivascular space. Because this
study does not provide direct evidence for the involvement of
exocytosis, another component of the transcytosis process, in the
ischemic border region of the extravasation of BSA, there is still
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the possibility that endothelial endocytosis is independent of BBB
opening. Additionally, transcytosis may possibly be involved in
the increase in BBB permeability by the delayed treatment of
rt-PA after ischemic stroke (Figure 2).
Endocytosis and the Multifunction of LRP
As previously described, LRP is a scavenger receptor that binds
a variety of biological ligands associated with the ECM, and it
is a major binding protein of rt-PA (Bu et al., 1992). LRP acts
as a membrane receptor of rt-PA, and its activation induces the
expressions of MMPs and VEGF (Wang et al., 2003; Suzuki et al.,
2009, 2015). The invasion of carcinoma cells is also decreased by
LRP silencing with RNA interference despite a strong stimulation
of pericellularMMP-2 and urokinase-type plasminogen activator
proteolytic activities (Dedieu et al., 2008). However, the precise
role of LRP in the regulation of ECM remodeling is still unclear.
During endocytosis, LRP does not act alone, as it has
membrane partners that vary according to numerous parameters,
including the cell origin, ECM composition, and pathological
conditions (Etique et al., 2013). LRP-mediated endocytosis of
soluble ligands is usually followed by intracellular lysosomal
routing and catabolism. LRP emerges as an endocytic receptor
regulating cellular matrix attachment sites and coordinating the
balance of adhesion/deadhesion. It has been known that a small
number of transmembrane proteins are associated with LRP. As
this association is thought to be involved in the endocytosis and
subsequent turnover of the membrane proteins, the mechanisms
are insufficient to be understood. As LRP is a major binding
FIGURE 2 | Schematic of the mechanisms of the increase in BBB
permeability by recombinant tissue-type plasminogen activator (rt-PA)
treatment after ischemic stroke. rt-PA activates the low-density lipoprotein
receptor-related protein (LRP), which is upregulated in endothelial cells (ECs)
by ischemic stress (1). The activation of LRP induces the transcriptional
upregulation of VEGF. Secreted VEGF binds to VEGFR-2 on the surface of
ECs through an autocrine mechanism and induces its phosphorylation (3). The
activation of VEGFR-2 leads to an increase in endocytosis and to the
activation of LRP, resulting in enhanced BBB permeability by endocytosis and
subsequent transcellular transport of proteins into cerebroparenchyma (4).
Tyr, TJ.
protein of t-PA, the administration of rt-PA may stimulate ECs
and accelerate the endocytosis of plasma proteins via LRP and
subsequent extravasation of proteins into the parenchyma.
rt-PA, Plasmin, and the Substrate for
Plasmin
It is unclear whether the involvements of rt-PAs during ischemia,
except for clot lysis, are associated with plasmin. Plasminogen
is essentially present in both blood and the brain under most
pathologic brain scenarios, especially together with rt-PA during
its utilization in ischemic stroke. Plasminogen is exclusively
localized in neurons of the cerebral cortex, hippocampus,
hypothalamus, and the cerebellum in rodents (Tsirka et al., 1997;
Basham and Seeds, 2001; Taniguchi et al., 2011). Hence, it is not
likely to be obviously assumed that brain-derived plasminogen
is activated at the BBB during stroke by endogenous t-PA.
Blood-derived plasminogen may be more readily available by
passing the BBB, and it may be activated at the BBB under an
ischemic condition. Therefore, brain-derived plasminogen in the
neuronal pathology may not be completely associated with BBB
permeability.
As previously described, plasmin can directly degrade
basement membrane components or cause degradation of
basement membrane components via the activation of MMPs
(Lijnen, 2001), which possess similar basement membrane
dismantling capabilities and damages the TJs (Jin et al., 2010).
rt-PA treatment did not alter ICB associated with stroke in mice
deficient in plasminogen and MMP-3, suggesting that plasmin
may be required to activate MMP-3 by rt-PA in ECs during
stroke (Suzuki et al., 2007).
Plasmin (and plasminogen) binds a wide array of cell-surface
receptors or binding proteins and cleaves a variety of biologic
substrates (Kwon et al., 2005; Miles and Parmer, 2013). As a
result of this capacity, plasmin has been understood to play a
role in many cellular responses, including cell migration, wound
healing, tissue remodeling, apoptosis, cancer invasion, cancer
metastasis, and inflammation and immunity, as extensively
reviewed elsewhere (Kwon et al., 2005; Syrovets et al., 2012;
Miles and Parmer, 2013). Together, these characters attribute
a position to plasmin as a sound candidate that participates
in the remodeling of cerebral blood vessels, especially during
stroke, when the BBBweakens and blood components gain access
to the BBB. The direct intracortical injection of concentrated
plasmin resulted in substantial lesion formation 6 h later,
accompanied by the oxidation of proteins and DNA, degradation
of occludin and collagen IV (basementmembrane), and elevation
of MMP-9, without the loss of ECs (Lukic-Panin et al., 2010).
These findings indicate that plasmin can evidently influence TJ
proteins and basement membrane. Therefore, it is likely that the
administration of rt-PA accelerates the likelihood of a plasmin-
dependent BBB alteration.
CONCLUSIONS
Delayed rt-PA treatment increases BBB permeability through a
number of mechanisms. Although the mechanisms depend on
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the degree of cell damage after ischemia, rt-PA has the possibility
of increasing BBB permeability without compromising BBB
integrity and causing subsequent BBB breakdown. rt-PA
increases BBB permeability via the induction of VEGF, which
at least partially mediates the subsequent increase in endothelial
endocytosis. Furthermore, an increase in BBB permeability
by endocytosis is likely the first step in BBB breakdown by
delayed rt-PA treatment combined with ischemic stroke because
various plasma proteins in the bloodstream are taken up by the
parenchyma across the compromised BBB.
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